A bioequivalence study of brand and generic clozapine in patients with schizophrenia. Pharmacokinetic and tolerability findings

Clinical Drug Investigation

Volumn 17, Issue 1, 1999, Pages 51-58

  Sramek, John J ^a   Anand, Ravi ^b   Hartman, Richard D ^b   Schran, Horst F ^b   Hourani, Jameel ^a   Barto, Sharon ^a   Wardle, Tom S ^a   Shiovitz, Thomas M ^a   Cutler, Neal R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; VERTIGO;

EID: 0032903155     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917010-00006     Document Type: Article

References (34)

1. Kane JM, Schooler NR, Marder SR, et al. Methods for clinical evaluation of pharmacologic treatments of schizophrenia. In: Prien RF, Robinson DS, editors. Clinical evaluation of psychotropic drugs. New York: Raven Press, 1994: 345-72
2. Jann MW. Clozapine. Pharmacotherapy 1991; 11 (3): 179-95
3. Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148 (2): 231-5
4. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm 1989; 8: 691-709
5. Ackenheil M. Clozapine - pharmacokinetic investigations and biochemical effects in man. Psychopharmacology (Berlin) 1989; 99 Suppl.: S32-S37
6. Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behavior, sex, and age. Psychopharmacology (Berlin) 1989; 99 Suppl.: S38-S40
7. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997; 171: 109-12
8. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYPI A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38 (5): 471-3
9. 1c receptor antagonists. Eur J Pharmacol 1996; 245 (2): 179-82
10. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55 Suppl. B: 133-6
11. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153 (12): 1579-84
12. Miller AL, Maas JW, Contreras S, et al. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Biol Psychiatry 1993; 34: 178-87
13. Gelijns AC. Modern methods of clinical investigation. Washington, DC: National Academy Press, 1990
14. Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res 1994; 11 (8): 1221
15. Food and Drug Administration. FDA update on clozapine guidelines. Rockville, MD, 1996
16. American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. 3rd ed revised. Washington, DC: American Psychiatric Press, 1987
17. Kay SR, Fizbein A, Opler IA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76
18. Choc MG, Lehr RG, Hsuan F, et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 1987; 4 (5): 402-5
19. Physician's Desk Reference. 51st ed. Montvale: Medical Economics Company, 1997: 2377
20. Choc MG, Hsuan F, Honigfeld G. et al. Single- vs. multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990; 7 (4): 347-51
21. Cheng YF, Lundberg T, Bondesson U, et al. Clinical pharmacokinetics of clozapine in chronic schizophrenia patients. Eur J Clin Pharmacol 1988; 34 (5): 445-9
22. Carpenter Jr WT, Conley RR, Buchanan RW, et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152 (6): 827-32
23. Ranjan R, Meltzer HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40 (4): 253-8
24. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153 (6): 759-64
25. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992: 4 (2): 187-95
26. Chacko RC, Hurley RA, Harper RG, et al. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995; 7 (4): 471-5
27. Safferman AZ, Kane JM, Aronowitz JS, et al. The use of clozapine in neurologic disorders. J Clin Psychiatry 1994: 55 Suppl. B: 98-101
28. Sramek JJ, Fresquet A, Marion-Landais G, et al. Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. J Clin Psychopharmacol 1996; 16 (6): 454-8
29. Grof P, Akhter MI, Campbell M, et al. Clinical evaluation of psychotropic drugs for psychiatric disorders: principles and proposed guidelines. Seattle: Hogrefe & Huber. 1993
30. Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995; 35 (8): 800-6
31. Goldberg MR, Barchowsky A, McCrea J, et al. Heptylphysostigmine (L-693,487): safety and cholinesterase inhibition in a placebo-controlled rising-dose healthy volunteers study [abstract]. Second International Springfield Symposium on Advances in Alzheimer Therapy; 1991 May. Springfield, IL, USA
32. Sramek JJ, Sedman AF, Reece PA, et al. Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 1995; 57 (5): 503-10
33. Cutler NR, Sramek JJ. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 1995; 48 (6): 421-8
34. Cutler NR, Sramek JJ. The target population in phase 1 clinical trials of cholinergic compounds in Alzheimer's disease: the role of the 'bridging study.' Alzheimer Dis Assoc Disord 1995; 9: 139-45